{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:03:41Z","timestamp":1793930621225,"version":"4.8.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm and Johan R\u00f6nnelid by Region Uppsala"},{"name":"B\u00f6rje Dahlin foundation"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Anti-TIF1-gamma autoantibodies can be detected with immunoprecipitation (IP), line blot (LB) and ELISA. We compared assay performance in patients with DM and the potential of these assays to detect anti-TIF1-gamma positive cancer-associated DM (CADM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included sera from 131 patients with DM followed at Karolinska University Hospital, Stockholm, Sweden and 82 healthy controls. Serum samples taken at DM diagnosis were tested for anti-TIF1-gamma autoantibodies with IP, two ELISAs (in-house and commercial) and LB. Cancer diagnosis and dates were obtained from the Swedish national cancer register. CADM was defined as a malignancy that developed within 3\u2009years of DM diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anti-TIF1-gamma autoantibodies were detected in 19\/101 (18.8%), 15\/113 (13.2%), 34\/131 (26%) and 45\/131 (34.4%) of the patients with IP, LB, in-house and commercial ELISA, respectively. The anti-TIF1-gamma results from the in-house ELISA were confirmed with IP in 93 of 101 (92%) cases, \u03ba\u2009=\u20090.76, with a commercial ELISA in 110 of 131 (84%) cases, \u03ba\u2009=\u20090.63, and with LB in 101 of 113 (89.3%) cases, \u03ba\u2009=\u20090.67. Anti-TIF1-gamma results with IP were confirmed with LB in 85 of 92 (92.4%) cases, \u03ba\u2009=\u20090.73. For detecting CADM, the anti-TIF1-gamma in-house ELISA had a sensitivity of 58% and specificity of 86%, the commercial ELISA had a sensitivity of 63% and specificity of 82%, IP had a sensitivity of 52% and specificity of 92%, LB had a sensitivity of 40% and specificity of 96%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The two anti-TIF1-gamma ELISA assays had advantages both for autoantibody detection and to identify anti-TIF1-gamma-positive CADM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac288","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:58:54Z","timestamp":1652774334000},"page":"4991-4996","source":"Crossref","is-referenced-by-count":22,"title":["ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-702X","authenticated-orcid":false,"given":"Sandra","family":"Selickaja","sequence":"first","affiliation":[{"name":"Department of Experimental, Preventive and Clinical Medicine, Center for Innovative Medicine"},{"name":"Department of Rheumatology, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-211X","authenticated-orcid":false,"given":"Angeles S","family":"Galindo-Feria","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet"},{"name":"Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital Solna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Dani","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet"},{"name":"Division of Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate school of Medicine"},{"name":"Ijinkai Takeda General Hospital , Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-3226","authenticated-orcid":false,"given":"Johan","family":"R\u00f6nnelid","sequence":"additional","affiliation":[{"name":"Department Immunology, Genetics and Pathology, Uppsala University , Uppsala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-5260","authenticated-orcid":false,"given":"Marie","family":"Holmqvist","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Karolinska University Hospital , Stockholm, Sweden"},{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet"},{"name":"Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital Solna"},{"name":"Division of Rheumatology, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulius","family":"Venalis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Karolinska University Hospital , Stockholm, Sweden"},{"name":"Division of Medicine, Section of Rheumatology, Danderyd University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"2022112912433528000_keac288-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"2022112912433528000_keac288-B2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. A systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022112912433528000_keac288-B3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/annrheumdis-2011-200871","article-title":"Anti-TIF1\u03b3 antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays","volume":"71","author":"Labrador-Horrillo","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022112912433528000_keac288-B4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022112912433528000_keac288-B5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0019-2791(71)90454-X","article-title":"Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G","volume":"8","author":"Engvall","year":"1971","journal-title":"Immunochemistry"},{"key":"2022112912433528000_keac288-B6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00415-019-09266-4","article-title":"Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study","volume":"266","author":"Montagnese","year":"2019","journal-title":"J Neurol"},{"key":"2022112912433528000_keac288-B7","doi-asserted-by":"crossref","first-page":"112661","DOI":"10.1016\/j.jim.2019.112661","article-title":"Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies","volume":"474","author":"Cavazzana","year":"2019","journal-title":"J Immunol Methods"},{"key":"2022112912433528000_keac288-B8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-c antibody in patients with dermatomyositis","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"key":"2022112912433528000_keac288-B9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2022112912433528000_keac288-B10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.23325","article-title":"Association of anti\u2013transcription intermediary factor 1c antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis","volume":"70","author":"Venalis","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022112912433528000_keac288-B11","first-page":"1048","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912433528000_keac288-B12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912433528000_keac288-B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/ket383","article-title":"Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation","volume":"53","author":"Aggarwal","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912433528000_keac288-B14","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912433528000_keac288-B15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2022112912433528000_keac288-B16","doi-asserted-by":"crossref","first-page":"625896","DOI":"10.3389\/fimmu.2020.625896","article-title":"Anti-TIF-1\u03b3 antibody detection using a commercial kit vs in-house immunoblot: usefulness in clinical practice","volume":"11","author":"Mariscal","year":"2021","journal-title":"Front Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac288\/45177930\/keac288.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4991\/47385942\/keac288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4991\/47385942\/keac288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:45:41Z","timestamp":1669707941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/12\/4991\/6586790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac288","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,5,17]]}}}